A major trial demonstrated the glucose-lowering drug empagliflozin reduces cardiovascular morbidity and mortality in individuals with Type 2 diabetes and existing cardiovascular disease. Clinicians and researchers discuss how it does so and who is most likely to benefit.
An acid in chicory could reduce impaired memory among people with Alzheimer’s disease and other neurodegenerative disorders, according to research in The FASEB Journal.
Scientists injected mice with lipopolysaccharide (LPS) to induce...
Research finds that young men in the middle- to high-normal range of BMI have elevated risk for heart failure when they reach middle age — earlier than heart failure typically develops.
An emphasis on evidence-based guidelines has yielded improvement in cardiovascular outcomes in recent years. However, with heart disease continuing to claim the lives of hundreds of thousands of Americans annually, even the most optimistic clinicians are not likely to unfurl the victory flag.
Arterial stiffness in people as young as their 40s can contribute to Alzheimer’s risk, data from the Framingham Heart Study show.
For many women, stopping hormone replacement therapy (HRT) may involve significant medical risk, recent research has found.
Approximately 58 million Americans — including two out of every five children between the ages of 3 and 11 — continue to be exposed to secondhand smoke, according to a recent report from the CDC.
Front-line strategies for treating prostate cancer vary significantly from physician to physician, according to a retrospective study in JAMA. Using the Surveillance, Epidemiology, and End Results cancer registries, researchers gathered information...
A group of nurses and clinicians at the University of California, San Francisco (UCSF) have created a strategy that hospitals may be able to apply toward solving one of health care’s most serious and costly issues: heart failure (HF) rehospitalization.
- 1 of 4
- next ›